Abstract: A system, computer program product, and method are provided to automate a framework for knowledge graph based persistence of data, and to resolve temporal changes and uncertainties in the knowledge graph. Natural language understanding, together with one or more machine learning models (MLMs), is used to extract data from unstructured information, including entities and entity relationships. The extracted data is populated into a knowledge graph. As the KG is subject to change, the KG is used to create new and retrain existing machine learning models (MLMs). Weighting is applied to the populated data in the form of veracity value. Blockchain technology is applied to the populated data to ensure reliability of the data and to provide auditability to assess changes to the data.

Abstract: A system, computer program product, and method are provided to automate a framework for knowledge graph based persistence of data, and to resolve temporal changes and uncertainties in the knowledge graph. Natural language understanding, together with one or more machine learning models (MLMs), is used to extract data from unstructured information, including entities and entity relationships. The extracted data is populated into a knowledge graph. As the KG is subject to change, the KG is used to create new and retrain existing machine learning models (MLMs). Weighting is applied to the populated data in the form of veracity value. Blockchain technology is applied to the populated data to ensure reliability of the data and to provide auditability to assess changes to the data.

Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.

Abstract: Methods and systems for using block chain technology to verify transaction data are described herein. A computing platform may receive data about events related to transactions, personal or corporate information, supply chains, and other relevant information about a person or corporate entity. The event information may be received, aggregated, and processed to determine metadata about the person or corporate entity. The metadata may indicate, for example, a trustworthiness of the person or corporate entity for various purposes. Such event information and/or metadata may be stored as transactions in a block chain that may be accessible by counterparties to a potential transaction involving the person or corporate entity. The automated event processing computing platform may further use automated techniques to implement smart transactions between the person/entity and counterparty based on the trust metadata.

Abstract: Methods and systems for using block chain technology to verify transaction data are described herein. A computing platform may receive data about events related to transactions, personal or corporate information, supply chains, and other relevant information about a person or corporate entity. The event information may be received, aggregated, and processed to determine metadata about the person or corporate entity. The metadata may indicate, for example, a trustworthiness of the person or corporate entity for various purposes. Such event information and/or metadata may be stored as transactions in a block chain that may be accessible by counterparties to a potential transaction involving the person or corporate entity. The automated event processing computing platform may further use automated techniques to implement smart transactions between the person/entity and counterparty based on the trust metadata.

Abstract: Methods, systems, and apparatuses for blockchain-based unexpected data detection are described herein. In some arrangements, a node within a decentralized peer-to-peer (e.g., P2P) network may receive a plurality of network function requests corresponding to the decentralized network. The node may analyze the plurality of network function requests to identify whether the requests included unexpected data and/or irregular data, and/or are associated with flagged wallets and/or smart contracts.

Abstract: Disclosed herein are compounds and methods for reducing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible Treg. In certain aspects, disclosed are compounds of Formula I-V.

Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.

Abstract: Systems for dynamically controlling data transmissions are provided. In some examples, a system may receive data from one or more computer systems. Data associated with an event may be extracted and the extracted data may be compared to one or more machine learning datasets to determine a likelihood that an issue associated with a computer system may occur. The system may determine whether the likelihood is greater than a predetermined threshold. If so, a modification to avoid the potential issue or mitigate an impact may be identified. The modification may be transmitted to and executed by the computer system to modify one or more aspects of the computer system. In some examples, one or more efficiency modifications may be identified based on the comparison of the extracted data to the machine learning datasets. The identified efficiency modification may be transmitted to and executed by the computer system to modify one or more aspects of the computer system.

Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.

Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S31-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.

Abstract: Disclosed are derivatives of icariin. Disclosed are compounds having Formula I-VIII as defined herein. Methods of using these compounds for the treatment of cancer and inflammation are also disclosed.

Abstract: We describe a touch sensitive holographic image display device for holographically projecting a touch sensitive image at an acute angle onto a surface on which the device is placed. The device includes holographic image projection optics comprising at least one coherent light source illuminating a spatial light modulator (SLM), output optics to project a hologram onto an acute angle surface, and a remote touch sensing system to remotely detect a touch of a location within or adjacent to the holographically displayed image. A control system is configured to provide data defining an image for display, to receive detected touch data, and to control the device responsive to remote detection of a touch of a the displayed image.

Abstract: We describe a touch sensitive image display device for projecting a touch sensitive displayed image at an acute angle onto a surface on which the device is placed. The device comprises: light sources to project two-dimensional first and second light distributions in respective first and second planes; and a multi-pixel sensor system to remotely detect touch of an area of said surface within or adjacent to the displayed image by detecting light from the first distribution to provide a detected touch signal. The multi-pixel sensor system also remotely detects presence of an object within the second light distribution to provide a detected presence signal. The device is configured to multiplex projection of the first light and second distributions. A controller has an input to receive the detected touch and detected presence signals and is configured to control the device responsive to these signals.

Abstract: We describe a touch sensitive image display device for projecting a touch sensitive displayed image at an acute angle onto a surface on which the device is placed, the device comprising: a first light source to project a first light distribution; a second light source to project a second light distribution; a touch sensor system to remotely detect touch of an area of said surface within or adjacent to said displayed image by detecting change of said first light distribution, and having an output to provide a detected touch signal; a presence sensor system to remotely detect presence of an object at least partially within said second light distribution by detecting change of said second light distribution, and having an output to provide a detected presence signal; a controller configured to control said device responsive to said detected touch signal and further configured to control said device responsive to said detected presence signal.

Abstract: Methods and devices for determining a preferred composition of anions in a liquid crystal device, and methods and devices for detecting a targeted agent in a sample using such preferred compositions, are disclosed. Such methods include the steps of preparing a liquid crystal device including a liquid crystal, a metal cation, a strongly coordinating anion, and a weakly coordinating anion, contacting the liquid crystal device with a sample suspected of including the targeted agent, and observing the orientational ordering of the liquid crystal at the surface.

Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S31-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.

Abstract: A method of displaying a video image comprises receiving sequential image frames at a processor. Each image frame is processed to obtain a kinoform. A programmable diffractive element such as an SLM represents the sequence of kinoforms allowing reproduction of the image using a suitable illumination beam.

Abstract: A method of displaying a video image comprises receiving sequential image frames at a processor. Each image frame is processed to obtain a kinoform. A programmable diffractive element such as an SLM represents the sequence of kinoforms allowing reproduction of the image using a suitable illumination beam.

Abstract: A method of displaying a video image comprises receiving sequential image frames at a processor. Each image frame is processed to obtain a kinoform. A programmable diffractive element such as an SLM represents the sequence of kinoforms allowing reproduction of the image using a suitable illumination beam.